Oligonucleotide-based Phosphorothioate Backbone Modification Service

Oligonucleotide-based Phosphorothioate Backbone Modification Service

The Advantages of Oligonucleotide-based Phosphorothioate Backbone Modification

With the deepening of the research, the scientists found that the functional nucleic acid composed of natural DNA and RNA was thermal stability and anti-nuclease degradation ability are not ideal. Therefore, chemists have attempted to introduce new functional groups into the structure of nucleic acids to give them more chemical modification sites and higher biological stability. Oligonucleotide-based phosphorothioate backbone modification is also a common method of modification. It not only improves the resistance of the nucleic acid sequence to enzymatic degradation but also enhances cellular endocytosis of the sequence, with higher biological activity. These modified nucleic acids folded into advanced structures with certain functions, and the stability of the sequences has been significantly improved, further broadening the application of functional nucleic acids.

Fig.1 Phosphate group modifications.Fig.1 Different generation of oligonucleotide modifications. (Egli, et al., 2005)

Oligonucleotide-based Phosphorothioate Backbone Modification Service at CD BioGlyco

At CD BioGlyco, we have several phosphorothioate backbone modification methods to achieve specific downstream applications or functions in the process of synthesizing oligonucleotides. When customizing the modified primers, we offer clients the choice of different modification positions and modification types.

  • Phosphorothioate Backbone Modification Service

The phosphorothioate backbone modification occurs naturally in two spin isomers, Rp and Sp. CD BioGlyco provides phosphorothioate backbone modification is a mixture of the two isomers. We introduce a sulfate bond between the 5-or the last 3-5 nucleic acids at the 3-end of the oligonucleotide to inhibit the degradation of exonucleotidyases. We have successfully synthesized a lot of high-quality Oligonucleotide Modification products so far. Moreover, we provide a variety of special chemical modifications and common modifications to satisfy the sequence synthesis and modification requirements of our clients.

  • Purification Service

We provide different purification methods including standard purification, PAGE-based purification, and HPLC-based purification.

Fig.2 Analysis of the oligonucleotide-based phosphorothioate backbone modification process.Fig.2 The process of oligonucleotide-based phosphorothioate backbone modification analysis. (CD BioGlyco)

Applications

  • Oligonucleotide-based phosphorothioate backbone modification can be used in miRNA therapy to protect and stabilize proteases and nucleases.
  • Oligonucleotide-based phosphorothioate backbone modification can be used in drug screening and disease treatment.
  • Oligonucleotide-based phosphorothioate backbone modification has been used in sequencing and cell-free cloning.
  • Oligonucleotide-based phosphorothioate backbone modification causes receptor-mediated signaling in platelets.
  • Phosphorothioate oligonucleotide modification has also been employed for the delivery of siRNAs via conjugation to an siRNA targeted to STAT3.

Advantages

  • Oligonucleotide-based phosphorothioate backbone modification supports custom modification sites at our company.
  • Oligonucleotide-based phosphorothioate backbone modification with strict quality control and a complete test system.

CD BioGlyco has been working on Carbohydrate Synthesis for many years and has accumulated a lot of experience in controlling process parameters to ensure high synthesis efficiency and product purity. We provide efficient and accurate Customized Sugar-nucleotide Services, including but not limited to Phosphorylation ModificationSugar Ring Modification, Base Modification, Linker Modification, and Fluorophore Modification. Please feel free to contact us for more information.

References

  1. Flierl, U.; et al. Phosphorothioate backbone modifications of nucleotidebased drugs are potent platelet activators. J Exp Med. 2015, 212(2): 129-137.
  2. Eckstein, F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 2014, 24(6): 374-387.
  3. Herkt, M.; Thum, T. Pharmacokinetics and proceedings in clinical application of nucleic acid therapeutics. Mol Ther. 2021, 29(2): 521-539.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.